EP-547 is under clinical development by Escient Pharmaceuticals and currently in Phase II for Pruritus. According to GlobalData, Phase II drugs for Pruritus have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EP-547’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EP-547 is under developmant for the treatment of cholestatic pruritus due to primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC), uremic pruritis, hepatitis B and hepatitis C. It is administered through oral route. It acts by targeting MRGPRX4 (Mas-related G Protein-Coupled Receptor-X4).
Escient Pharmaceuticals overview
Escient Pharmaceuticals is a pharmaceutical and healthcare company. It develops and commercialize drugs targeting G protein-coupled receptor (GPCRs) for unmet medical needs. The company aims to develop therapies for neuro-immuno-inflammatory and autoreactive diseases. In addition, it’s MrgprX4 and MrgprX2 for treatment of cholestatic and uremic pruritus. It is funded by Osage University Partners, The Column Group and 5AM Ventures, Sanofi Ventures, Cowen, Perceptive Advisors, Redmile Group and Altitude Life Science Ventures. Escient Pharmaceuticals is headquartered in San Diego, California, the US.
For a complete picture of EP-547’s drug-specific PTSR and LoA scores, buy the report here.